A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis

Wiens, A., Correr, C. J., Venson, R. , Grochocki, M. C., Otuki, M. F. and Pontarolo, R. (2009) A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clinical Rheumatology, 28(12), pp. 1365-1373. (doi: 10.1007/s10067-009-1233-9) (PMID:19771491)

Full text not currently available from Enlighten.

Abstract

Infliximab is a chimeric monoclonal antibody. Published studies indicate that its use in patients with rheumatoid arthritis can be efficient in providing long-term benefits. The aim of this study is to evaluate the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials that compared intravenous administration of 3 mg/kg body weight infliximab or placebo in patients concomitantly using methotrexate. Only studies of moderate or high quality were included. A meta-analysis was conducted to assess the efficacy (based on changes of American College of Rheumatology (ACR) criteria) and the safety (based on serious adverse events, serious infections, malignancy, and deaths) of infliximab use. Withdrawals due to adverse events or lack of efficacy were also evaluated in both infliximab-treated and control groups. Seven trials met the inclusion criteria, comprising 2,129 patients. In the efficacy meta-analysis, a greater number of infliximab-treated patients relative to those in the placebo group achieved ACR20, ACR50, and ACR70 values from 14 weeks to 2 years of treatment. For safety analysis, there were no statistically significant differences between the groups. Withdrawals due to adverse events were higher in the infliximab group relative to the placebo group, and withdrawals due to lack of efficacy were higher in the placebo group relative to the infliximab-treated group. This meta-analysis shows a higher efficacy of infliximab relative to placebo without significant safety differences between the infliximab-treated and control groups.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Venson, Dr Rafael
Authors: Wiens, A., Correr, C. J., Venson, R., Grochocki, M. C., Otuki, M. F., and Pontarolo, R.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Clinical Rheumatology
Publisher:Springer
ISSN:0770-3198
ISSN (Online):1434-9949
Published Online:22 September 2009

University Staff: Request a correction | Enlighten Editors: Update this record